Screen Readers Skip to Content

New Therapeutic Target for Huntington's and Parkinson's Disease

Published : 2014-01-08
Author : University of Western Ontario - Contact: Kathy Wallis - kwallis3@uwo.ca - 519-661-2111 x81136

Synopsis: Research from Western University has revealed a possible new target for treating movement disorders such as Huntingtons disease (HD) and Parkinsons disease.

Main Digest

Stephen Ferguson, PhD, a scientist at Western's Robarts Research Institute, and Fabiola Ribeiro, PhD, of the Universidade Federal de Minas Gerais in Brazil found a definite improvement in motor behaviors in a HD mouse model when one of the major neurotransmitters in the brain, called Metabotropic Glutamate Receptor 5 (mGluR5) was deleted.

The research is published online in Human Molecular Genetics.

HD is an inherited neuro-degenerative disorder which causes uncontrolled movement, and eventually cognitive decline and emotional disturbances.

Working in the Ferguson lab where Ribeiro was a postdoctoral trainee, the scientists crossed two mouse models. One was a mouse which doesn't have glutamate receptors - they've been knocked out genetically, and the other is a HD mouse model which over-expresses mutant human Huntington protein. They found if they deleted mGluR5, they lost the pathology of Huntington's in the neurons, and they saw improvements in motor behavior which normally would be impaired in these mice.

"What we found was, if we block mGluR5, which is the glutamate receptor we're interested in, the mice become hyper locomotive so they become able to move better than wild type mice suggesting glutamate receptors might be a good target for treating movement disorders such as Parkinson's disease. So that was a bit of a surprise that came out in the study, and we can show that genetically and pharmaceutically," says Ferguson who holds a Canada Research Chair in Molecular Neurobiology. "And the good thing is, there are mGluR5 antagonists now in stage three clinical trials for diseases such as Fragile X, so it is quite possible these drugs will be available for patients in the future."

You're reading Disabled World. See our homepage for informative disability news, reviews, sports, stories and how-tos. You can also connect with us on social media such as Twitter and Facebook or learn more about Disabled World on our about us page.

Disclaimer: Disabled World provides general information only. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World. View our Advertising Policy for further information. Please report outdated or inaccurate information to us.

Cite Page: Journal: Disabled World. Language: English (U.S.). Author: University of Western Ontario. Electronic Publication Date: 2014-01-08. Title: New Therapeutic Target for Huntington's and Parkinson's Disease, Source: <a href=https://www.disabled-world.com/medical/clinical-trials/therapeutic.php>New Therapeutic Target for Huntington's and Parkinson's Disease</a>. Retrieved 2021-06-14, from https://www.disabled-world.com/medical/clinical-trials/therapeutic.php - Reference: DW#340-10026.